Document Detail


Xamoterol in patients with dilated cardiomyopathy: an increase in beta-receptors in lymphocytes.
MedLine Citation:
PMID:  2908309     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Xamoterol, a partial-beta 1 agonist, was administered orally (100 mg, twice daily) to healthy volunteers (n = 8) and to patients with heart failure (n = 8) for one week. The density (Bmax) and affinity (Kd) of lymphocyte beta-receptors were lower in the patients with heart failure than in the healthy volunteers (Bmax = 931 +/- 214 vs 1466 +/- 373 sites/cell, and Kd = 0.60 +/- 0.11 vs 1.07 +/- 0.14 nM). During treatment with xamoterol, Bmax (7169 +/- 3768 and 7749 +/- 3807 sites/cell) and Kd (6.01 +/- 3.84 and 9.06 +/- 4.66 nM) increased strikingly (p less than 0.01) in both groups. For 12 months, xamoterol (100 mg bd) was given in the same manner to 10 patients with dilated cardiomyopathy. The long-term effects after three and 12 months were assessed. Xamoterol reduced the cardiothoracic ratio from 57 +/- 6% to 55 +/- 5% after three months and 54 +/- 5% after 12 months of treatment (both p less than 0.05), and increased exercise tolerance from 5 +/- 2 min to 7 +/- 2 min and to 7 +/- 2 min (p less than 0.01, p less than 0.05). Echocardiographic fractional shortening increased from 13 +/- 6% to 20 +/- 8% (p less than 0.01) and to 20 +/- 10% (p less than 0.05). Pulmonary wedge pressure during exercise at the same work load decreased from 40 +/- 12 mmHg to 25 +/- 9 mmHg (p less than 0.01) in three months; whereas pulmonary wedge pressures during exercise or at rest in 12 months were unchanged. Exercise heart rate decreased from 118 +/- 9 beats/min to 106 +/- 6 beats/min in three months (p less than 0.01), but was unchanged in 12 months. Bmax and Kd of the beta-receptors increased from 1024 +/- 413 sites/cell and 0.67 +/- 0.27 nM to 1976 +/- 497 sites/cell and 1.60 +/- 0.42 nM (both p less than 0.01), respectively, in three months, and 1584 +/- 650 sites/cell (NS) and 1.21 +/- 0.54 nM (p less than 0.05), respectively, in 12 months. It is concluded that xamoterol improves exercise tolerance, hemodynamics and resolves subjective symptoms for certain patients with dilated cardiomyopathy by its actions as a beta-agonist and beta-antagonist during longterm treatment.
Authors:
K Watanabe; Y Hirokawa; A Shibata
Related Documents :
2756879 - Comparison of the effects of pindolol and propranolol on exercise performance in young ...
2532179 - Beta-endorphin, catecholamines, and cortisol during exhaustive endurance exercise.
16368719 - Beta-adrenergic receptor trafficking by exercise in rat adipocytes: roles of g-protein-...
2908309 - Xamoterol in patients with dilated cardiomyopathy: an increase in beta-receptors in lym...
9832149 - Traumatic brain injury increases beta-amyloid peptide 1-42 in cerebrospinal fluid.
2859199 - Comparative beta-adrenoceptor blocking effect and pharmacokinetics of bucindolol and pr...
16381489 - Association of outdoor air pollution with chronic respiratory morbidity in an industria...
19661449 - Adenosine receptor antagonist and augmented vasodilation during hypoxic exercise.
24314679 - Exercise in multiple sclerosis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiology     Volume:  18     ISSN:  0914-5087     ISO Abbreviation:  J Cardiol     Publication Date:  1988 Dec 
Date Detail:
Created Date:  1989-10-31     Completed Date:  1989-10-31     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8804703     Medline TA:  J Cardiol     Country:  JAPAN    
Other Details:
Languages:  eng     Pagination:  1015-25     Citation Subset:  IM    
Affiliation:
Division of Cardiology, Kuwana Hospital, Niigata.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adaptation, Physiological
Adrenergic beta-Agonists / therapeutic use*
Adult
Cardiomyopathy, Dilated / blood,  drug therapy*
Female
Heart Failure / drug therapy
Hemodynamics / drug effects
Humans
Lymphocytes / analysis*
Male
Middle Aged
Physical Exertion
Propanolamines / therapeutic use*
Receptors, Adrenergic, beta / analysis*
Xamoterol
Chemical
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Propanolamines; 0/Receptors, Adrenergic, beta; 81801-12-9/Xamoterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Response rate with respect to the blood pressure-lowering effect of the vasodilating and beta-blocki...
Next Document:  Kinetic analyses of transmitter release in neuromuscular transmission.